Blackrock is focused on applications that we can see being deployed, having patient impact and generating revenue in the next year or three years. We feel for this kind of technology to progress, to get to the next levels, it needs to have efficacy today. And I think what we will see is that the risk of invasiveness will drop. People will become a little bit more comfortable with it. The reason why we don't have these technologies benefiting patients today is because the efficacy wasn't there. It was not high enough and the risk was too concerning. That's what we will rebalance and I think we will see deployment increasingly of less invasive, semi invasive and even invasive technologies.